Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. Laboratory diagnosis of haematological malignancies is dependent on combining several technologies, including morphology, immunophenotyping, cytogenetics and molecular genetics correlated clinical details and classification according to the current WHO guidelines. The concept of the Specialised Integrated Haematological Malignancy Diagnostic Services (SIHMDS) has evolved since the UK National Institute for Health and Care Excellence (NICE) Improving Outcomes Guidance (IOG) in 2003 and subsequently various models of delivery have been established. As part of the 2016 update to the NICE IOG, these models were systematically evaluated and recommendations produced to form the basis for quality standards for future development of SIHMDS. We provide a summary of the systematic review and recommendations. Although the recommendations pertain to the UK National Health Service (NHS), they have relevance to the modern delivery of diagnostic services internationally.
- MOLECULAR GENETICS
- FLOW CYTOMETRY
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Handling editor Mary Frances McMullin
Contributors All authors were members of the Guideline Committee for the updated National Institute for Health and Care Excellence Improving Outcomes Guidance in Haematological Cancer and contributed to the writing of the manuscript and approved the final version; the manuscript was led by John A Snowden (as Clinical Lead of the Guideline Committee) and Fergus Macbeth as (Chair of the Guideline Committee), and supported by Susan O'Connell (Researcher for systematic reviews) and James Hawkins (as Health Economist). CD, AJ, DM, CM, MS, GS and ES were members of the Guideline Committee with expertise in the diagnosis in haematological cancer.
Funding This work was undertaken by the National Collaborating Centre for Cancer, which received funding from the National Institute for Health and Care Excellence (NICE). The views expressed in this publication are those of the authors and not necessarily those of NICE.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.
Data sharing statement The updated National Institute for Health and Care Excellence (NICE) Improving Outcomes Guidance in Haematological Cancer is available on the NICE website.